Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.97
Ensysce Biosciences, Inc. shareholders approved Amendment of the Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan to increase the aggregate number of shares that may be issued from 31,296 shares to 617,092 shares at the 2023-08-24 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-08-24
Exact text from the filing
202,246.08 50,153 1,500 1,484,119
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.97
Ensysce Biosciences, Inc. shareholders approved Election of Class II Directors at the 2023-08-24 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-08-24
Exact text from the filing
Bob Gower 222,281.08 20,963 10,655 1,484,119 Curtis Rosebraugh 223,255.08 11,605 9,039 1,484,119
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.97
Ensysce Biosciences, Inc. shareholders approved Ratification of appointment of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-08-24 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-08-24
Exact text from the filing
Non-Votes 1,631,139.08 16,004 90,875 0 A quorum being present, votes properly cast “FOR” the proposal constituted a majority of votes cast on the matter, with “ABSTENTIONS”
View on SEC.gov